Amdizalisib

安迪利塞

Report date: 2025/02/10 11:28:17
NME

Base Information

Drug NameAmdizalisib
Drug Alias NameAndiliseHMPL-689
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsLymphoma, FollicularLymphoma, B-Cell, Marginal ZoneLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHutchmed (Hong Kong) LtdHutchison Medipharma Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, B-Cell, Marginal ZoneLymphoma, B-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A